Regular exercise testing is recommended for all people with cystic fibrosis (PwCF). A range
of validated tests, which integrate both strength and aerobic function, are available and …

Cystic fibrosis (CF) is a potentially fatal monogenic disease that causes a progressive
multisystemic pathology. Over the last decade, the introduction of CF transmembrane …

Background: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators
represent targeted therapies directly acting on the CFTR channel. The triple therapy …

Aims Combined CFTR modulator therapies have dramatically altered pulmonary outcomes
in patients with cystic fibrosis (CF). Their impact on glucose metabolism requires further …

Cystic fibrosis (CF) is an autosomal recessive genetic disorder resulting from defects in the
cystic fibrosis transmembrane conductance regulator (CFTR) protein, which in turn results in …

Elexacaftor/tezacaftor/ivacaftor (ETI) has made a substantial positive impact for people living
with CF (pwCF). However, there can be substantial variability in efficacy, and we lack …

The course of cystic fibrosis (CF) as a nutritional illness is diverging since the introduction of
highly effective modulator therapy, leading to more heterogeneous phenotypes of the …

Purpose: Maintaining physical fitness plays an important role in the management of people
with cystic fibrosis (pwCF). Longitudinal data on the course of physical fitness and the …

Cystic fibrosis (CF) is one of the most common genetic diseases with around 70,000 affected
patients worldwide. CF is a multisystem disease caused by a mutation in the CF …

Background Habitual physical activity (PA) and exercise training are accepted as important
aspects of care for people with cystic fibrosis (pwCF) to improve health-related measures of …